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Mutations in DNMT3B Modify
Epigenetic Repression of the D4Z4 Repeat
and the Penetrance of Facioscapulohumeral Dystrophy
Marlinde L. van den Boogaard,1,11 Richard J.L.F. Lemmers,1,11 Judit Balog,1,11 Marie¨lle Wohlgemuth,2
Mari Auranen,3 Satomi Mitsuhashi,4 Patrick J. van der Vliet,1 Kirsten R. Straasheijm,1
Rob F.P. van den Akker,1 Marjolein Kriek,1,5 Marlies E.Y. Laurense-Bik,5 Vered Raz,1
Monique M. van Ostaijen-ten Dam,6 Kerstin B.M. Hansson,5 Elly L. van der Kooi,7 Sari Kiuru-Enari,3
Bjarne Udd,8 Maarten J.D. van Tol,6 Ichizo Nishino,4 Rabi Tawil,9 Stephen J. Tapscott,10
Baziel G.M. van Engelen,2 and Silve`re M. van der Maarel1,*
Facioscapulohumeral dystrophy (FSHD) is associatedwith somatic chromatin relaxation of the D4Z4 repeat array and derepression of the
D4Z4-encoded DUX4 retrogene coding for a germline transcription factor. Somatic DUX4 derepression is caused either by a 1–10 unit
repeat-array contraction (FSHD1) or by mutations in SMCHD1, which encodes a chromatin repressor that binds to D4Z4 (FSHD2).
Here, we show that heterozygous mutations in DNA methyltransferase 3B (DNMT3B) are a likely cause of D4Z4 derepression associated
with low levels ofDUX4 expression from the D4Z4 repeat and increased penetrance of FSHD. Recessive mutations in DNMT3Bwere pre-
viously shown to cause immunodeficiency, centromeric instability, and facial anomalies (ICF) syndrome. This study suggests that tran-
scription of DUX4 in somatic cells is modified by variations in its epigenetic state and provides a basis for understanding the reduced
penetrance of FSHD within families.Facioscapulohumeral dystrophy (FSHD [OMIM: 158900
and 158901]) is a common muscular dystrophy typically
manifesting in the second decade and characterized by
progressive weakness and atrophy of the facial and up-
per-extremity muscles. With disease progression, other
muscles also become affected.1 A clinical hallmark of the
disease is the variability in onset and progression, such
that 20% of mutation carriers eventually become wheel-
chair dependent, and a similar proportion of mutation
carriers remain asymptomatic.2
The common form of the disease, FSHD1, is associated
with a 1–10 unit contraction of the polymorphic D4Z4
macrosatellite repeat array on chromosome arm 4q (Figure
1A).3,4 In the healthy control population, this array varies
from 8 to 100 units, and 1%–3% of individuals carry an
FSHD-sized allele of 8–10 units.5,6 Each unit of the repeat
array contains a copy of the retrogene double homeobox
4 (DUX4 [OMIM: 606009]), which is normally expressed
in the testis and silenced in somatic tissue.7 In FSHD1,
the epigenetic repression ofDUX4 is incomplete in somatic
cells, leading to sporadic DUX4 expression in myonu-
clei.7,8 Stable DUX4 transcripts are only produced in com-
bination with a polymorphic polyadenylation signal (PAS)
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(4qA-S and 4qA-L) (Figure 1A).9 Contractions of the highly
homologous repeat arrays in 4qB or 4q10 are non-patho-
genic because of the absence of a DUX4 PAS.9
Somatic repression of DUX4 requires a combination
of epigenetic mechanisms, and D4Z4 hypomethylation
has consistently been reported as an aberrant epigenetic
feature in FSHD.10–13 In FSHD1, D4Z4 hypomethylation
is restricted to the contracted allele. In the rare FSHD2
type of the disease, D4Z4 hypomethylation is observed
on all D4Z4 repeat arrays in the absence of D4Z4 con-
tractions (Figure 1A).14,15 D4Z4 methylation linearly corre-
lates with the size of the D4Z4 array in control and
FSHD-affected individuals.16 FSHD2-affected individuals
often carry smaller but normally sized D4Z4 repeat arrays
(8–20 units), given that this renders themmore susceptible
to further D4Z4 hypomethylation.14,16 Dominant segrega-
tion of D4Z4 hypomethylation in FSHD2-affected families
was instrumental in identifying mutations in SMCHD1
(structural maintenance of chromosomes flexible hinge
domain-containing 1 [OMIM: 614982]) in >85% of these
families.17 SMCHD1 is a chromatin repressor involved in
the establishment and/or maintenance of CpG methyl-
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Figure 1. D4Z4LocusandFSHD2-Affected
Families
(A) Schematic representation of the D4Z4
locus. In control individuals, the D4Z4
repeat array ranges from 8 to 100 units
and shows characteristics of a closed chro-
matin structure (black triangles) character-
ized by high CpG methylation, among
other things. For both FSHD1 and FSHD2,
the chromatin adopts a more open config-
uration (white triangles) marked by a loss
of CpG methylation and other chromatin
changes. FSHD1 is caused by a contraction
of the D4Z4 repeat to 1–10 units, whereas
FSHD2 involves chromatin relaxation due
to mutations that affect a chromatin mod-
ifier (black dots), most often SMCHD1. The
chromatin relaxation must occur in a
permissive 4qA (marked by 4qA-S in this
figure) or 4qA-L chromosomal region to
cause FSHD, given that 4qB chromosomes
are non-permissive for FSHD (chromo-
some 4 variants are displayed in the dashed
boxes).9 4qA-S and 4qA-L differ by the
length of the last partial D4Z4 unit, and
protein studies have demonstrated produc-
tion of DUX4 from both 4qA variants. The
30 UTR of DUX4 is missing in 4qB chro-
mosomal regions (white square in dashed
box), which makes them non-permissive
to DUX4 expression.
(B and C) Pedigrees of families Rf210 (B)
and Rf732 (C). Clinically affected individ-
uals are indicated in black. The key shows
the family identifier (ID), Delta1 score,
age at examination (AAE), and size of the
smallest D4Z4 repeat array on a FSHD-
permissive allele (4qA-S and 4qA-L). Addi-
tionally, it indicates when no permissive
allele was present (4qB only). The cDNA
position behind the family ID indicates
the cDNA position of the DNMT3B muta-
tion (GenBank: NM_006892.3) present in
this family. The asterisk indicates individ-
uals carrying the DNMT3B mutation.Therefore, the disease presentation in FSHD2 depends on a
combination of repeat length and damaging potential of
the SMCHD1mutation.16 Mutations in SMCHD1 have also
been reported as modifiers of disease severity in FSHD1-
affected families with alleles of 8–10 D4Z4 units.20,21 Thus,
D4Z4 methylation is dependent on repeat-array size and
on theactivity of thepartially characterizedD4Z4-repressive
mechanisms.Deviations in theexpectedD4Z4methylation,
expressed as theDelta1 factor, canbediagnostic for thepres-
ence of damaging variants in D4Z4-chromatin modifiers.
Indeed, Delta1 factors % 22% are generally associated
with mutations in SMCHD1.16The American Journal of Human GBecause FSHD2 cannot be ex-
plained by SMCHD1 mutations in all
affected families, we applied exome
sequencing in eight families in whom
we found D4Z4 hypomethylation
without evidence of an exonicSMCHD1 mutation (Figures 1B and 1C and Figure S1). All
samples were obtained in an anonymized manner, and all
families gave consent. The study was approved by themed-
ical ethics committees of the Leiden University Medical
Center and the Radboud University Medical Center Nijme-
gen. Whole-exome sequencing (WES) was performed by
deCODE Genetics (Reykjavik) in the context of the Euro-
pean Union’s NeurOmics project. To identify variants, we
analyzed the WES data by using the deCODE Clinical
Sequence Miner. We performed dominant analysis for
multiple case and control individuals and annotated gene
variants (with moderate to high Variant Effect Predictorenetics 98, 1020–1029, May 5, 2016 1021
Figure 2. DNMT3B Mutations in FSHD2
(A) Schematic representation of DNMT3B.
The amino acid changes (GenBank:
NP_008823.1) found in FSHD2-affected
families are indicated in red.
(B and C) Sanger sequence confirmation
of DNMT3B variants (GenBank: NM_
006892.3) in Rf210 and Rf732.
(D and E) Multiple-sequence alignment
(MSA) of DNMT3B across distinct species
for DNMT3B variants in Rf210 and Rf732.
MSA was performed with ClustalOmega,
and alignment was viewed in Jalview and
colored as in ClustalX.
(F) Ribbon representation of the nuclear-
magnetic-resonance structure of the ADD
domain of ATRX (PDB: 2JM1).22 The
cysteine residues are shown as sticks.
Cys527 is shown in magenta. Zinc ions
are represented as spheres.
(G) Ribbon representation of the crystallog-
raphy structure of the C-terminal domain
of DNMT3A (chain A [PDB: 2QRV]). The
proline residues are shown as sticks.
Pro691 is shown in magenta.consequences) to identify possible dominant mutations.
Under these conditions, in two families we identified
a potentially damaging variant in DNMT3B (DNA methyl-
transferase 3B [OMIM: 602900]), encoding a known D4Z4-
chromatin modifier. These variants have not been reported
previously in dbSNP, the 1000 Genomes Project, the Na-
tional Heart, Lung, and Blood Institute Exome Sequencing
Project (ESP) Exome Variant Server, the Exome Aggregation
Consortium (ExAC) Browser, or in-house databases.
Family Rf210 is a FSHD1-affected family with a 9 unit
D4Z4 array in a permissive 4qA chromosomal region
(Figure 1B andTable S1). Despite the presence of this disease
allele in seven family members, only four of them are1022 The American Journal of Human Genetics 98, 1020–1029, May 5, 2016clinically affected, whereas one carrier
(Rf210.102 [I-2]) couldnot be clinically
examined. D4Z4 methylation at the
FseI site was determined by South-
ern blotting and was expressed as
theDelta1 score, which is the observed
methylation corrected for the size of
the repeat array at the FseI site in
D4Z4.16 In Rf210, analysis of D4Z4
methylation identified robust D4Z4
hypomethylation in two severely
affected individuals (Rf210.201 [II-1]
and Rf210.212 [II-5]) and one
clinically unaffected individual
(Rf210.319 [III-6]), as evidenced by
the strongly reduced Delta1 values.
These reduced Delta1 values indicate
the involvement of a defective D4Z4-
chromatin modifier. Genetic studies
excluded the involvement of the
SMCHD1 locus (Figure S2), but exomesequencing identified a potentially damaging DNMT3B
variant co-segregatingwithD4Z4hypomethylation (Figures
2A and 2B and Table S1). This variant (c.1579T>C
[p.Cys527Arg] [GenBank: NM_006892.3]) was confirmed
by Sanger sequencing and disrupts the C2C2-type zinc-
fingermotif in the ATRX-DNMT3-DNMT3L (ADD) domain,
a highly conserved domain that can be found in several
chromatin-associated proteins that play a role in estab-
lishing and/or maintaining a normal DNA-methylation
pattern (Figures 2B, 2D, and 2F).22,23 Like SMCHD1,
DNMT3B was previously identified as a suppressor of
murine metastable epialleles, alleles that display unusual
variable expressivity in the absence of genetic heterogeneity
dependingon their epigenetic state.18,24,25 In theseDnmt3b-
hypomorphic mice, the ADD domain also seems to be pri-
marily affected.26
In family Rf210, the DNMT3B variant perfectly segre-
gates with D4Z4 hypomethylation, but not with disease
presentation. DNMT3B-mutation carrier Rf210.319 (III-6;
Figure 1B) might be protected from disease presentation
because of the large size of the FSHD-permissive D4Z4
repeat (44 units). This is reminiscent of the situation
in SMCHD1-mutation carriers, where individuals with
smaller, normally sized D4Z4 repeat arrays (8–20 units)
have a greater likelihood of developing FSHD than do indi-
viduals with larger repeat arrays.16 The two DNMT3B-
variant carriers with a 9 unit D4Z4 array, however, have
an age-corrected clinical severity score (ACCS) greater
than that of the carriers of only a 9 unit D4Z4 allele. This
suggests that the DNMT3B variant acts as a modifier of dis-
ease severity in this FSHD1-affected family, similarly to the
SMCHD1 mutation in FSHD1-affected families.20 Of the
four carriers of a 9 unit D4Z4 array without the DNMT3B
variant, two are clinically unaffected (Rf210.104 [I-3] and
Rf210.303 [III-2]). This variability in severity is typical for
this borderline-FSHD1 repeat-array size. Indeed, 1%–3%
of the control population carries an 8–10 unit array on
a permissive allele, demonstrating the strongly reduced
penetrance of these alleles.5,6 Penetrance is dependent on
age and the degree of D4Z4-chromatin relaxation in
somatic tissue, among other things.12,16,27
In family Rf732, the index individual (Rf732.3 [II-1])
carries a 13 unit D4Z4 repeat array in a 4qA chromosomal
region (Figure 1C and Table S1), and it is also present in
his unaffected father and brother. Methylation analysis
showed that Rf732.3 (II-1) and his father (Rf732.1 [I-1])
had severe D4Z4 hypomethylation on all four alleles with
reduced Delta1 values. Exome sequencing identified a
potentially damaging variant affecting a highly conserved
residue in the enzymatic domain of DNMT3B (DNMT3B
c.2072C>T [p.Pro691Leu] [GenBank: NM_006892.3]) in
the index individual and his father; it was confirmed by
Sanger sequencing and was absent in the son with normal
D4Z4 methylation (Figures 2A, 2C, 2E, and 2G). Although
Rf732.1 (I-1) and Rf732.3 (II-1) both carry this DNMT3B
variant, have the same Delta1 value, and have a 13 unit
FSHD-permissive D4Z4 allele, only Rf732.3 (II-1) is clini-
cally affected. This family emphasizes the reduced pene-
trance that is typical of FSHD.16,27 The Delta1 value in
this family is low, but not as low as typically found in
SMCHD1-mutation carriers.16 This suggests a lesser degree
of D4Z4-chromatin relaxation in this family, which might
explain why the father has remained unaffected.
Analysis of all coding exons of DNMT3B in 25 additional
individuals with a permissive D4Z4 allele and mildly to
severely reduced D4Z4 methylation, but not exonic
SMCHD1mutations, did not identify additional mutations
in DNMT3B (Tables S2 and S4).
Biallelic DNMT3B mutations have been reported in
autosomal-recessive immunodeficiency, centromeric insta-The Americbility, and facial anomalies syndrome type 1 (ICF1 [OMIM:
242860]).28,29 This primary immunodeficiency syndrome
is characterized by hypo- or agammaglobulinemia with
B cells and by a distinct facial appearance. There is a pro-
gressive decrease in B and T cells during childhood and
adolescence.30,31 The cytogenetic hallmark of ICF syn-
drome is the presence of chromosome abnormalities
involving the juxtacentromeric domains of chromosomes
1, 9, and 16 in metaphase spreads of phytohemagglutinin
(PHA)-stimulated cells.30,32 ICF1-affected individuals show
CpG hypomethylation of juxtacentromeric satellite repeat
types II and III and the macrosatellite repeats NBL2 and
D4Z4.33,34 ICF1 mutations most often affect the catalytic
domain of DNMT3B and are believed to result in strongly
reduced DNMT3B activity.31
Because our data suggest that FSHD2 and ICF1 can both
be caused by DNMT3B mutations—dominant mutations
for FSHD2 and recessive mutations for ICF1—we analyzed
six ICF1 individuals belonging to five families (Rf285,
Rf286, Rf614, Rf699, and Coriell Cell Repositories family
2081, here annotated as Rf1178) for D4Z4 repeat arrays,
the presence of a DUX4 PAS, D4Z4 hypomethylation, and
DUX4 expression (Figure 3). If possible, we also included
unaffected relatives. Table S3 lists all ICF1-affected families
with reference to their original description.Consistentwith
earlier reports,33 methylation analysis showed that all ICF1
individuals tested had severe D4Z4 hypomethylation with
Delta1 values varying between35% and46% (Figure 3).
However, depending on the mutation, some heterozy-
gous carriers (parents of Rf699 and mother of Rf1178) also
showed reduced Delta1 values, similar to what we observed
in our FSHD2-affected families (19% to 26%). This not
only suggests an additive effect of bothDNMT3Bmutations
in the affected ICF1 children but also puts ICF1-mutation
carriers with a reduced Delta1 value at risk of stable DUX4
expression and FSHD if the mutation is combined with a
DUX4 PAS. Analysis of D4Z4-repeat sizes, however, showed
that about half of the heterozygousDNMT3B carriers in our
ICF1-affected families donot carry a FSHD-permissive chro-
mosome. For those who do have D4Z4 repeat arrays on
FSHD-permissive chromosomes (containing a DUX4 PAS),
the arrays arewell beyond the size ofwhat is typically found
in FSHD2 individuals (Figure 3). The smallest permissive
D4Z4 repeat array found in these heterozygous DNMT3B
carriers contained 32 units, suggesting that these indi-
viduals might be protected from somatic DUX4 expres-
sion because of their long D4Z4 repeat arrays, given
that in FSHD2, we already demonstrated a D4Z4-repeat-
size-dependent penetrance for SMCHD1 mutations.16 In
concordance, to our knowledge,muscleweakness hasnever
been reported in ICF1-mutation carriers.
To address the possibility of DUX4 expression in carriers
of a single DNMT3B mutation, we trans-differentiated
primary fibroblasts of control individuals, FSHD1 and
FSHD2 individuals, and unaffected and affected carriers
of an FSHD2 mutation in DNMT3B (Rf210.319 [III-6] in
Figure 1B and Rf732.3 [II-1] in Figure 1C, respectively)an Journal of Human Genetics 98, 1020–1029, May 5, 2016 1023
Figure 3. Pedigrees of Families Rf286,
Rf699, Rf1178, Rf285, and Rf614, Affected
by Autosomal-Recessive ICF1
Affected individuals are indicated in
black, and DNMT3B mutations (GenBank:
NM_006892.3) are shown below each in-
dividual. Their clinical phenotypes and
DNMT3B mutations have been described
before.28,30,31,35,36 The key description is
identical to that in Figure 1.into myotubes by lentiviral MyoD expression. A lentivirus
containing GFP or FLAG was used as a control. To examine
differentiation, we measured MYOG (OMIM: 159980) and
MYH3 (OMIM: 160720) expression levels by qPCR.37,38
For almost all cell lines, we observed MYOG and MYH3
expression only in the fibroblasts transduced with MyoD,
indicating that these cells were trans-differentiated into
myogenic cells (Figure 4A). In one FSHD2 cell line
(FSHD2-1), MYH3 expression was detected in the GFP-
transduced fibroblast as well, possibly because of a
technical or biological artifact. We next analyzed the
expression of DUX4 and three DUX4 target genes (LEUTX,
TRIM43, and PRAMEF2) by qPCR and gel electrophoresis.39
We found expression of DUX4 and DUX4 target genes in
MyoD-transduced fibroblasts of FSHD2-affected individual
Rf732.3 (II-1, who has a 13 unit D4Z4 repeat array), but not
in unaffected individual Rf210.319 (III-6, who has a 44
unit array in a 4qA chromosomal region) (Figure 4A and
Figure S3A). No DUX4 expression or upregulated expres-
sion of DUX4 target genes was detected in GFP-transduced
fibroblasts, and no fibroblasts were available from other
FSHD2-affected family members. These data are consistent
with the suggestion that heterozygous DNMT3B muta-
tions, only when combined with smaller D4Z4 repeat ar-
rays, can derepress DUX4 in somatic cells and cause FSHD.
To investigate DUX4 expression in ICF1, we trans-differ-
entiated three primary fibroblast cell lines of ICF1 individ-
uals (Rf699.2 [II-1], Rf614.1 [I-1], and Rf1178.2 [II-1];
Figure 3). In Rf699.2 (II-1), who has a 32 unit permissive
D4Z4 array, we detected DUX4 in the MyoD-transduced
fibroblasts (Figure S3B). DUX4 could not be detected
in Rf614.1 (I-1) because she carries two 4qB alleles,
which are unable to produce a stable DUX4 transcript1024 The American Journal of Human Genetics 98, 1020–1029, May 5, 2016(Figure S3B). Our DUX4 primers
recognize the most common DUX4-
4A-S variant, but not the DUX4-4A-L
variant, which is produced from
4qA-L repeats. Because Rf1178.2
(II-1) carries a 4qA-L repeat, we were
unable to directly detect DUX4
(Figure S3B). However, the expression
of DUX4 target genes was detected in
Rf1178.2 (II-1), suggesting that these
fibroblasts produce DUX4 (Figure 4A
and Figure S3A). These results show
that MyoD-transduced fibroblasts inICF1-affected individuals can produce small amounts of
DUX4, indicating that when both DNMT3B alleles are
mutated, the epigenetic derepression is sufficient to facili-
tate DUX4 expression from D4Z4 repeats (Figure S3B).
Additionally, myotubes were available from one ICF1 indi-
vidual from a different family (Rf285.1 [I-1]; Figure 3); this
individual has an 11 unit D4Z4 repeat on a FSHD-permis-
sive chromosome 4, and we detected small amounts of
DUX4 by immunofluorescent staining (Figure 4B). This
ICF1 individual (Rf285.1 [I-1]) might still be too young
(15 years) to develop FSHD. Possibly, the short life expec-
tancy of ICF1 individuals in general might obscure the
diagnosis of muscle weakness.
Conversely, although ICF1-mutation carriers are reported
to be unaffected, we explored the possibility that dominant
DNMT3B mutations identified in our FSHD2-affected fam-
ilies might have epigenetic consequences similar to those
found in ICF1 or clinical features reminiscent of ICF syn-
drome. Metaphase analysis of PHA-stimulated peripheral-
blood mononuclear cell cultures of FSHD DNMT3B-muta-
tion carrier Rf210.319 (III-6; Figure 1B), but not Rf732.3
(II-1, Figure 1C), indicated a low frequency of formation of
multi-branchedchromosomes (Figures5Aand5B).Chromo-
somedecondensations, breaks, anddeletionscanbe foundat
low frequencies also in ICF1-mutation carriers and control
individuals,32 but the formation ofmulti-branched chromo-
somes might be specific to the presence of DNMT3B muta-
tions, even in heterozygous carriers. Rf210.319 (III-6) also
showed evidenceofmildNBL2hypomethylation ina South-
ernblot assay, giventhat theNBL2repeat is sensitive todiges-
tion by the methylation-sensitive endonuclease Eco52I,
albeit to a lesser degree than observed in ICF1 individuals
(Figure 5C). Similarly, one heterozygous ICF1-mutation
Figure 4. DUX4 Presence in FSHD and ICF1
(A) Expression ofMYOG,MYH3,DUX4, and LEUTX (DUX4 target) by qPCR inGFP (G)- orMyoD (M)-lentivirus-transduced fibroblasts from
control individuals, FSHD1andFSHD2cell lines, and individualsRf210.319,Rf732.3, and ICF-affectedRf1178.2.All transductionswereper-
formed twice for eachcell line, except for control individual4 (13 transducedwithGFPand23 transducedwithMyoD)andFSHD2-2 (trans-
duced 13with GFP and 13withMyoD). Mean expression values with SDs are shown in relation to those of the reference genesGUSB and
RPL27. DUX4 was measured with primers for the most common DUX4-4A-S variant, but the primers did not recognize DUX4-4A-L. The
fibroblasts from control individual 4 and Rf1178.2 carry a 4qA-L allele and were therefore excluded from analysis of DUX4 expression.
Primers are listed in Table S5.
(B) Immunofluorescent staining for DUX4 and Myosin in fixed ICF1 myotubes from Rf285.1 (Figure 3) shows DUX4 immunoreactivity
in a small percentage of myotubes.carrierwith strongly reducedDelta1values forD4Z4 (Rf699.1
[I-1]; Figure 3) also showed mild NBL2 hypomethylation
(Figure 5C). The fact that not all carriers of the same variant
showed NBL2 hypomethylation suggests that heterozygous
DNMT3B variants can cause mild and variable NBL2 hypo-
methylation.Clinically,however,DNMT3B-mutationcarrier
Rf210.319 (III-6) and his siblings, Rf210.316 (III-4) and
Rf210.317 (III-5), do not show signs or features of ICF syn-
drome and have normal serum immunoglobulin levels and
normal numbers of B cells and T cell subsets (Figure S4).
These observations raise the question of why DNMT3B
mutations can cause such discordant phenotypes. Muta-
tions that affect the ADD domain of DNMT3B have never
been reported in ICF syndrome, but mutations disrupting
theADDdomainofDNMT3AhavebeenassociatedwithTat-
ton-Brown-Rahman syndrome (OMIM: 615879), an over-
growth syndrome with intellectual disability.41 Similarly,
mutations that disturb the ADD domain of ATRX have
been reported in alpha thalassemia-mental retardation syn-
drome, X-linked (ATR-X [OMIM: 301040]).22 The ADD do-
mains of ATRX, DNMT3A, and DNMT3B bind to the N ter-The Americminus of the histone 3 (H3) tail lacking the active lysine 4
(H3K4) methylation mark, where they integrate histone-
modification status with DNA methylation.42 Binding of
the ADD domain of DNMT3A to the H3 tail stimulates the
catalytic activity of this enzyme.43–45 Likewise, it is possible
that themutation that affects the ADD domain of DNMT3B
in family Rf210 also disrupts the DNA-methylation activity
of DNMT3B. However, most of the ICF1 mutations, such
as the mutation in family Rf732, are located in exons that
encode the catalytic domain of DNMT3B. It is not well
known why mutations in DNMT3B cause a primary immu-
nodeficiency, but the absence of an immunological pheno-
type in our FSHD2 families might be explained by the
presenceof onewild-typeDNMT3B allele, given that hetero-
zygous ICF1-mutation carriers also do not present with
immunological abnormalities.
Our study implicates that mutations in DNMT3B act as
a modifier in FSHD. We propose that, like for SMCHD1,
the effect of DNMT3B mutations on DUX4 expression
and disease presentation depends on the presence of a
DUX4 PAS and on the size of the D4Z4 repeat array. This,an Journal of Human Genetics 98, 1020–1029, May 5, 2016 1025
Figure 5. Metaphase Analysis and NBL2 Southern Blot Analysis of Rf210, Rf732, and ICF1-Affected Families
(A)Metaphaseswere analyzed from three heterozygousDNMT3B-mutation carriers (Rf210.319, Rf732.3, and Rf1178.3), one ICF1 individual
(Rf1178.2), and three individualswithout aDNMT3B variant (Rf210.316, Rf210.317, and Rf1178.1). Identifiers fromLeidenUniversityMed-
ical Center and Coriell, themutation inDNMT3B (GenBank: NM_006892.3), and the number of analyzedmetaphases are indicated. Chro-
mosomal anomalies are listed in the last column.
(B) Four panels show examples of chromosomal anomalies identified in individual Rf210.319. Chromosomal anomalies are indicated
with red arrows.
(C)NBL2 Southern blot analysis in Rf210, Rf732, and ICF1-affected families after digestion of 2 mg genomic DNAwith themethylation-sen-
sitive endonuclease Eco52I according to previously described protocols.40 Numbers correspond with pedigrees in Figures 1 and 3. Delta1
scores are indicated in brackets. NBL2was only hypomethylated in the four individuals indicated with an asterisk.combined with the relatively young age at which ICF1
individuals typically succumb to their immunodeficiency,
might explain the absence of FSHD in ICF1-affected
families. These observations also suggest that FSHD1 and
FSHD2 represent polar extremes of a continuous disease1026 The American Journal of Human Genetics 98, 1020–1029, Maymechanism determined by the interaction among D4Z4-
repeat size, the presence of a DUX4 PAS, and variations
in genes thatmodify the D4Z4 epigenetic state and provide
a firm basis for understanding reduced disease penetrance
in the FSHD population.5, 2016
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